| Literature DB >> 25802534 |
Haliza Abdul Mutalib1, Sharanjeet Kaur1, Ahmad Rohi Ghazali1, Ng Chinn Hooi1, Nor Hasanah Safie1.
Abstract
Purpose. An open-label pilot study of virgin coconut oil (VCO) was conducted to determine the safety of the agent as ocular rewetting eye drops on rabbits. Methods. Efficacy of the VCO was assessed by measuring NIBUT, anterior eye assessment, corneal staining, pH, and Schirmer value before instillation and at 30 min, 60 min, and two weeks after instillation. Friedman test was used to analyse any changes in all the measurable variables over the period of time. Results. Only conjunctival redness with instillation of saline agent showed significant difference over the period of time (P < 0.05). However, further statistical analysis had shown no significant difference at 30 min, 60 min, and two weeks compared to initial measurement (P > 0.05). There were no changes in the NIBUT, limbal redness, palpebral conjunctiva redness, corneal staining, pH, and Schirmer value over the period of time for each agent (P > 0.05). Conclusion. VCO acts as safe rewetting eye drops as it has shown no significant difference in the measurable parameter compared to commercial brand eye drops and saline. These study data suggest that VCO is safe to be used as ocular rewetting agent on human being.Entities:
Year: 2015 PMID: 25802534 PMCID: PMC4352907 DOI: 10.1155/2015/135987
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Mean (±SD) for study eyes at each time point using different types of drops. (Agent I: VCO, agent II: saline, and agent III: Tears Naturale II.)
| Mean (±SD) | Agent | 0 min | 30 min | 60 min | 2 weeks |
|---|---|---|---|---|---|
| NIBUT | I | 20.76 ± 2.36 | 19.71 ± 2.10 | 20.26 ± 2.26 | 20.61 ± 1.96 |
| II | 22.52 ± 2.60 | 22.34 ± 3.59 | 22.44 ± 3.05 | 23.40 ± 3.30 | |
| III | 22.70 ± 1.57 | 23.71 ± 2.24 | 24.31 ± 3.03 | 24.31 ± 3.29 | |
|
| |||||
| Corneal staining | I | 0.83 ± 0.29 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| II | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
| III | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
|
| |||||
| Limbal hyperemia | I | 0.83 ± 0.29 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| II | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
| III | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
|
| |||||
| Conjunctival hyperemia | I | 0.83 ± 0.29 | 1.33 ± 0.29 | 1.50 ± 0.00 | 1.00 ± 0.00 |
| II | 0.67 ± 0.58 | 1.50 ± 0.00 | 1.50 ± 0.00 | 0.50 ± 0.50 | |
| III | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
|
| |||||
| Palpebral hyperemia | I | 0.83 ± 0.29 | 1.33 ± 0.29 | 1.50 ± 0.00 | 1.00 ± 0.00 |
| II | 0.67 ± 0.58 | 1.50 ± 0.00 | 1.50 ± 0.00 | 0.50 ± 0.50 | |
| III | 1.00 ± 0.00 | 1.17 ± 0.29 | 1.33 ± 0.29 | 0.83 ± 0.29 | |
|
| |||||
| Schirmer test | I | 1.00 ± 0.00 | 1.33 ± 0.29 | 1.33 ± 0.29 | 1.00 ± 0.00 |
| II | 0.67 ± 0.58 | 0.67 ± 0.58 | 0.83 ± 0.76 | 1.00 ± 0.50 | |
| III | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
|
| |||||
| pH | I | 7.67 ± 0.19 | 7.67 ± 0.38 | 7.89 ± 0.22 | 8.00 ± 0.39 |
| II | 7.34 ± 1.45 | 7.67 ± 0.38 | 7.67 ± 0.19 | 7.56 ± 1.06 | |
| III | 6.66 ± 0.88 | 6.67 ± 0.96 | 7.22 ± 0.73 | 7.11 ± 0.22 | |
Mean (±SD) for control eyes at each time point without drops.
| Mean (±SD) | 0 min | 30 min | 60 min | 2 weeks |
|---|---|---|---|---|
| NIBUT | 19.65 ± 1.53 | 19.60 ± 1.49 | 20.63 ± 2.06 | 19.81 ± 1.89 |
| 20.82 ± 1.37 | 20.63 ± 1.75 | 20.71 ± 2.43 | 19.28 ± 1.20 | |
| 21.74 ± 1.99 | 20.33 ± 1.41 | 19.85 ± 1.64 | 20.80 ± 0.92 | |
|
| ||||
| Corneal staining | 0.83 ± 0.29 | 0.83 ± 0.29 | 0.83 ± 0.29 | 0.83 ± 0.29 |
| 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
| 1.33 ± 0.58 | 1.33 ± 0.58 | 1.33 ± 0.58 | 0.83 ± 0.29 | |
|
| ||||
| Limbal hyperemia | 0.83 ± 0.29 | 0.83 ± 0.29 | 0.83 ± 0.29 | 0.83 ± 0.29 |
| 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
| 1.33 ± 0.58 | 1.33 ± 0.58 | 1.33 ± 0.58 | 0.83 ± 0.29 | |
|
| ||||
| Conjunctival hyperemia | 0.83 ± 0.29 | 1.00 ± 0.00 | 1.17 ± 0.29 | 1.00 ± 0.00 |
| 1.00 ± 0.00 | 1.33 ± 0.29 | 1.33 ± 0.29 | 0.50 ± 0.50 | |
| 1.00 ± 0.00 | 1.17 ± 0.29 | 1.17 ± 0.29 | 1.00 ± 0.00 | |
|
| ||||
| Palpebral hyperemia | 0.83 ± 0.29 | 1.00 ± 0.00 | 1.17 ± 0.29 | 1.00 ± 0.00 |
| 1.00 ± 0.00 | 1.33 ± 0.29 | 1.33 ± 0.29 | 0.50 ± 0.50 | |
| 1.00 ± 0.00 | 1.17 ± 0.29 | 1.17 ± 0.29 | 1.00 ± 0.00 | |
|
| ||||
| Schirmer test | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.83 ± 0.29 | |
| 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | |
|
| ||||
| pH | 7.67 ± 0.00 | 7.56 ± 0.59 | 7.56 ± 0.11 | 7.33 ± 0.33 |
| 8.66 ± 0.67 | 8.44 ± 0.73 | 8.89 ± 0.29 | 8.00 ± 0.33 | |
| 7.11 ± 0.29 | 7.11 ± 0.78 | 7.33 ± 0.51 | 7.55 ± 0.22 | |
Figure 1Changes of NIBUT value for tested eye.